Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing

Rhea-AI Summary

Castle Biosciences, Inc. (CSTL) announced that CFO Frank Stokes has been recognized as one of Finance & Investing’s Top 25 CFOs of Houston for 2023. This accolade reflects his contributions to the company, particularly during its IPO in 2019 and the acquisitions of Cernostics and AltheaDx. Stokes has been instrumental in facilitating financial growth and operational advancements since joining Castle in December 2017. The company focuses on innovative diagnostic tests that enhance patient care and has a diverse portfolio addressing skin cancers, Barrett’s esophagus, and mental health conditions.

Positive

• CFO Frank Stokes named among Finance & Investing's Top 25 CFOs of Houston for 2023, highlighting his financial expertise.
• Stokes' leadership contributed to Castle's successful IPO in 2019 and strategic acquisitions in recent years.

Negative

• None.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023. This year’s awardees are financial executives at the forefront of the rapid technological development occurring throughout Houston across key global industries, including energy, life sciences, manufacturing, logistics and aerospace.

“I am proud of Frank’s accomplishments at Castle,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We believe his recognition among Houston’s Top 25 CFOs is a testament to his financial acuity and keen business acumen, which have been an asset to our organization and supported our financial and operational growth.”

Having served as Castle’s chief financial officer since December 2017, Stokes was instrumental in the Company’s initial public offering in 2019 and the Company’s acquisitions of Cernostics, Inc. and its TissueCypher® Barrett’s Esophagus test in 2021, and AltheaDx, Inc. and its IDgenetix® test for mental health conditions in 2022. Prior to joining Castle, Stokes served as chief financial officer for Hammock Pharmaceuticals, and as a managing director of Leerink Swann (now SVB Leerink), Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. Stokes holds a B.S. degree in business administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.

The full list of Finance & Investing’s Top 25 CFOs of Houston for 2023 can be viewed here.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

About Finance & Investing

Finance & Investing is a comprehensive source for research and information, business news and corporate actions related to investment banking, wealth management and the public and private markets. The firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on finance and investing and the various firms and executives that make up the sector. Finance & Investing and its affiliates circulate its content to over 38,000 individuals and businesses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005015/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

Who is Castle Biosciences' CFO recognized in 2023?

Frank Stokes was recognized as one of Finance & Investing's Top 25 CFOs of Houston in 2023.

What achievements has Frank Stokes accomplished at Castle Biosciences?

Frank Stokes was instrumental in the company's IPO in 2019 and acquisitions of Cernostics and AltheaDx.

What does Castle Biosciences specialize in?

Castle Biosciences focuses on innovative diagnostic tests for conditions such as skin cancers, Barrett’s esophagus, and mental health.

When did Frank Stokes become CFO of Castle Biosciences?

Frank Stokes has served as CFO of Castle Biosciences since December 2017.

What is the stock symbol for Castle Biosciences?

The stock symbol for Castle Biosciences is CSTL.